Dec 01, 2021 / 10:10PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Hello, everyone. Thank you for joining us. Pleasure to have Pfizer management join us. There's a lot to talk about, but at the outset, I do want to say that when we were first scheduling this event, there was a lot of interest at Pfizer at the time. And this was -- we were doing this in the -- in -- during the summer, and there was a lot of interest at Pfizer at the time to talk about some of the innovation areas that aren't getting necessarily much Street focus, which included obviously an emerging gene therapy pipeline. And one of the goals at this fireside when we were first setting it up was to have Bob Smith, who's -- who could really take us through the gene therapy business in a lot of detail. But of course, we couldn't have predicted that 3 days before this fireside chat, there would obviously be a new and crazy variant.
So in light of that, we're going to start off with a few variant questions, if that's okay. But let me first turn it over to Chris, who's the new head
Pfizer Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 02, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers